🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "huge turning point" in the fight against drug-resistant strains of the bacteria, according to researchers.

A Global Challenge

Gonorrhoea infections are increasing worldwide, with estimates suggesting over 82 million instances annually. Especially elevated rates are reported in Africa and nations within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. Across England, cases have hit a historical peak, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an important and timely step in the face of rising global incidence, escalating drug resistance and the highly restricted available drugs presently on offer.”

Health officials are deeply concerned about the increase in drug-resistant strains. The global health body has listed it as a "priority pathogen". Recent surveillance showed that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Treatment Options Secure Authorization

One new antibiotic, also known as a brand name, was cleared by the American regulatory agency in December for combating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Researchers believe that targeted use of this new drug will help delay the emergence of superbugs.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This treatment, which is employed against UTIs, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment emerged from a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to see it through.

“This authorization represents a huge turning point in the therapy of multidrug-resistant gonorrhoea, which previously has been evolving faster than medical innovation.”

Research Study Data and Worldwide Availability

As per results detailed in a major medical journal, zoliflodacin successfully treated more than 90% of uncomplicated infections. This establishes an equal footing with the existing first-line therapy, which uses a dual-drug approach. The trial included hundreds of participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the authority to register and commercialise the drug in many developing nations.

Doctors directly involved have expressed optimism. Access to a easy-to-administer therapy like this is seen as a "game-changer" for gonorrhoea control. This is considered crucial to alleviate the strain of the disease for patients and to halt the transmission of highly drug-resistant gonorrhoea around the world.